Circio (CRNA) Status update summary

Technology platform and innovation

• Developed a proprietary circular RNA (circVec) platform enabling enhanced and prolonged gene expression for gene and cell therapy applications.

• circVec offers up to 75x longer half-life and 40x higher protein expression in vivo compared to conventional mRNA approaches.

• Demonstrated significant improvements in heart, eye, and CNS gene expression, with up to 40x increased activity in heart tissue.

• circVec enables dose reduction in AAV gene therapy, lowering toxicity and cost while maintaining efficacy.

• In vivo cell therapy applications show >6 months expression duration, outperforming mRNA-based approaches.

Market opportunity and partnerships

• Targeting large patient populations in heart, eye, and CNS genetic diseases, as well as cancer and autoimmune disorders.

• Recent industry deals in AAV gene therapy and in vivo cell therapy highlight strong commercial interest, with transactions up to $2.1 billion.

• Entered first partnership with a global pharma company in Q4 2025, with additional collaborations targeted.

Financial update and rights issue

• Announced an 88% underwritten and presubscribed NOK 50 million rights issue, priced at NOK 1.00 per share.

• Rights issue supported by major shareholders, with NOK 24.2 million in presubscription commitments.

• Funds will support operations for 12 months and enable delivery of key pre-clinical milestones, including a feasibility study with a major pharma partner.

• Subscription period runs from 15–29 January 2026, with attached warrants exercisable in June 2026.